# Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer

> **NCT00324415** · PHASE2 · COMPLETED · sponsor: **AIDS Malignancy Consortium** · enrollment: 45 (actual)

## Conditions studied

- Anal Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** cisplatin
- **DRUG:** fluorouracil
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00324415
- **Lead sponsor:** AIDS Malignancy Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2014-04
- **Final completion:** 2016-05
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-05-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00324415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00324415, "Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00324415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*